公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
2020 | Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study | Mehnert J.M.; Bergsland E.; O’Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU ; Le Tourneau C.; Hollebecque A.; Élez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. | Cancer | 83 | 75 | |
2021 | Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors | Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; CHIA-CHI LIN ; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. | Clinical Cancer Research | 24 | 21 |